bPiDDB (peripherally administered) inhibits nicotine-evoked dopamine (DA) release in nucleus accumbens and decrease intravenous nicotine self-administration in rats[1]. bPiDDB is brain bioavailable following peripheral administration and is transported actively by the blood-brain barrier choline transporter into the central compartment[1].
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment (File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)
Remove